By modifying the drug release characteristics, significant therapeutic benefits can be achieved, such as improved efficacy of the therapeutic agent, reduced adverse effects, optimization of the dosing scheme, and overall improvement in patient compliance. There are numerous approaches for modified release, each with its own benefits and drawbacks. This webinar will present PVA, a fully-synthetic polymer, for optimized sustained release matrix formulations. Combining robust and reliable gel-forming behavior with optimized tableting properties, PVA provides solutions for the most challenging sustained-release formulations.
In this webinar, you will learn:
Gudrun Birk, Ph.D.
Head of Controlled Release
Gudrun is a pharmacist by education and has been with Merck since April 2014. Within the R&D organization, she and her team focus on the development of innovative new excipients and functional excipients systems for solid oral dosage forms. She presents research results at scientific conferences and in publications as well as provides customers with guidance and support for their unique formulation challenges. Gudrun studied pharmacy at the University of Freiburg, Germany, and holds a Ph.D. from Ludwig Maximilian University of Munich, Germany.